On the morning of October 22nd, Fenghuang Town successfully signed a contract with Suzhou Womei Biotechnology Co., Ltd. for the "Womei Biosynthetic CDMO Factory" project, which is the first project to settle in Feixiang Pharmaceutical Industrial Park since its approval. Teng Xiaonuo, General Manager of Suzhou Womei Biotechnology Co., Ltd., Professor Ren Guobin, Vice Dean of the Research Institute of East China University of Science and Technology, Wang Weimin, Secretary of the Phoenix Town Party Committee, Tian Wenhua, Deputy Secretary of the Town Party Committee and Mayor, Ji Xiaoyang, Deputy Secretary of the Town Party Committee, and others participated in the signing.

This project is based on leading process control and intelligent manufacturing technologies at home and abroad, and aims to establish a green intelligent factory that integrates consumables, process engineering, and equipment. It balances production efficiency and cost control, and strives to build a first-class synthetic biology CDMO industry base in China, providing high-quality contract development and production services for the biomanufacturing industry.
The total investment of the project is 500 million yuan, and it is expected to achieve an annual fermentation capacity of 10000 tons after completion. It will undertake more than 50 CDMO projects annually, incubate more than 10 technology patents annually, and generate an output value of 500 million to 1 billion yuan, promoting regional economic development and forming a cluster effect in the biotechnology industry. The project services cover multiple fields such as active pharmaceutical ingredients, biomaterials, food, and agriculture, which can effectively shorten the product research and development and large-scale production cycle by 30% -40%, and enhance the industrialization process. It can directly create over 300 high-tech employment positions and drive over 1000 indirect employment positions.

It is reported that Womei Biotechnology was founded in 2020 and is one of the first high-tech enterprises in China to achieve large-scale research and production of personalized culture media. The company has now formed a business scope centered around biopharmaceuticals (animal protection and human use), key upstream technology services in synthetic biology, and related products. Among them, cell culture media and bioreactors are the two main product lines of the company, and the product matrix covers personalized culture media, cell and fermentation reactors, high-throughput equipment, biochemical reagents, etc. We have over 80 patents and have passed international authoritative certifications such as ISO9001 quality management system, ISO13485 medical device quality management system, and DMF filing for FDA culture medium. We firmly hold the core supplier position in the upstream and downstream industry chain of biotechnology. In 2023, we will achieve a tax payment of nearly 20 million yuan, and in 2024, Suzhou Womei will be awarded honors such as "National Specialized, Refined, Unique and New Little Giant".

Synthetic biology has become a rapidly growing new business sector for Womei Biotechnology, with its main development direction being "process engineering equipment integration". In the next five years, Womei Biotechnology will continue to deeply cultivate the upstream links of the biotechnology industry chain, not only providing full process equipment for process development, but also providing engineering design and synthetic biology CDMO services for users.

According to incomplete statistics, Shandong Lingkai, a subsidiary of listed pharmaceutical company Huashen Technology, is currently positioned as a synthetic biology CDMO company. It has established a large-scale production and transformation base for CDMO/synthetic biology and chemistry industries. In addition, companies such as Zhongyao Biology and Bochuang Synthetic Biology also have layouts here.

Source: https://pharm.jgvogel.cn/c1456042.shtml